sr141716 has been researched along with Disease Models, Animal in 180 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.56) | 18.2507 |
| 2000's | 87 (48.33) | 29.6817 |
| 2010's | 85 (47.22) | 24.3611 |
| 2020's | 7 (3.89) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Doss, GA; Finke, PE; Fong, TM; Lao, JZ; Mills, SG; Plummer, CW; Schaeffer, MT; Shearman, LP; Shen, CP; Strack, AM; Stribling, DS; Tong, X; Van der Ploeg, LH; Wang, J | 1 |
| Chandran, P; Dart, MJ; Daza, AV; El-Kouhen, OF; Frost, JM; Garrison, TR; Grayson, GK; Hsieh, GC; Li, L; Meyer, MD; Miller, LN; Pai, M; Tietje, KR; Yao, BB; Zhu, CZ | 1 |
| Alig, L; Alsenz, J; Andjelkovic, M; Bénardeau, A; Bendels, S; Bleicher, K; Bourson, A; David-Pierson, P; Guba, W; Hildbrand, S; Kube, D; Lübbers, T; Mayweg, AV; Narquizian, R; Neidhart, W; Nettekoven, M; Plancher, JM; Rocha, C; Rogers-Evans, M; Röver, S; Schneider, G; Taylor, S; Waldmeier, P | 1 |
| Beers, DS; Brodbeck, RM; Chenard, BL; Guo, Q; Hammer, J; Hutchison, AJ; Kershaw, M; Krause, JE; Mao, J; Maynard, GD; Near, KE; Wustrow, DJ; Yuan, J; Zhao, H; Zhou, D | 1 |
| Boström, J; Cheng, L; Greasley, PJ; Hjorth, S; Nordberg, H; Olsson, RI; Ryberg, E; Tholander, J | 1 |
| Borst, AJ; Kruse, CG; Lange, JH; van der Neut, MA; van Stuivenberg, HH; van Vliet, BJ; Yildirim, M | 1 |
| Chen, JZ; Chen, LL; Han, S; Pu, JB; Qian, HY; Xie, X; Zhang, FF | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Hassan, R; Mahmoud, MF; Rezq, S | 1 |
| Binda, KH; Brooks, DJ; Chacur, M; Landau, AM; Real, CC | 1 |
| Dimmito, MP; Dvorácskó, S; Minosi, P; Mollica, A; Pieretti, S; Stefanucci, A; Tömböly, C; Zengin, G | 1 |
| Kang, Y; Kim, D; Lee, GJ; Lee, JY; Lee, PR; Oh, SB; Won, CH | 1 |
| Chen, J; Chen, Y; Dou, ZJ; Gao, XL; Jia, YL; Liu, T; Wang, B; Wang, MT; Wu, SJ; Yang, C; Yang, JJ; Zhang, N | 1 |
| Stavreva, GT; Tashev, RE; Velikova, MS | 1 |
| Doncheva, D; Tashev, R; Velikova, M | 1 |
| Dou, ZJ; Hu, ZX; Liu, T; Wang, B; Wang, MT; Zhao, L | 1 |
| Grel, A; Metna-Laurent, M; Mondésir, M; Piazza, PV; Vallée, M | 1 |
| El-Kerdasy, HI; Hussien, NI; Ibrahim, ME | 1 |
| Bifulco, G; Bifulco, M; Bizzarro, V; Feoli, A; Fiore, D; Franceschelli, S; Gazzerro, P; Laezza, C; Lauro, G; Piscopo, C; Proto, MC; Sbardella, G; Tosco, A | 1 |
| Banks, ML; Bradshaw, HB; Crowe, MS; Kinsey, SG; Leishman, E; Prather, PL; Wilson, CD | 1 |
| Chen, Y; Liu, S; Luo, X; Shen, Y | 1 |
| Chen, Y; Dong, Y; Dou, Z; Gao, X; Huang, Y; Qiao, Y; Wang, B; Wu, S | 1 |
| Agbemenyah, H; Beißbarth, T; Del Río, JA; Di Marzo, V; Gil, V; Havemann-Reinecke, U; Hoyer-Fender, S; Lorenzen, S; Moore, TP; Piscitelli, F; Pommerenke, C; Quintana, E; Ramió-Torrentà, LL; Salinas, G; Tomas-Roig, J | 1 |
| Ahmad, U; Chen, X; Damaj, MI; Donvito, G; Jackson, KJ; Lichtman, AH; McIntosh, JM; Muldoon, PP; Zaveri, NT | 1 |
| Jorgačević, B; Mladenović, D; Radosavljević, T; Todorović, V; Vesković, M; Vučević, D; Vukićević, D; Vukićević, RJ | 1 |
| Bosch, F; Busquets-Garcia, A; de la Torre, R; Dierssen, M; Falcón-Moya, R; Garzón-Montesinos, C; Gomis-González, M; Maldonado, R; Martín-García, E; Navarro-Romero, A; Ozaita, A; Pastor, A; Piazza, PV; Pizarro, N; Revest, JM; Rodríguez-Moreno, A; Vázquez-Oliver, A | 1 |
| McMahon, LR; Schulze, DR; Wilkerson, JL | 1 |
| Davies, AJ; Kim, D; Lee, JY; Oh, SB; Park, J; Pickering, AE; Vang, H | 1 |
| Butler, P; Munafò, MR; Nutt, DJ; Robinson, ES; Stuart, SA | 2 |
| Bajza, A; Literáti-Nagy, B; Literati-Nagy, Z; Mandl, J; Szilvássy, Z; Tory, K; Vígh, L | 1 |
| Bhandari, U; Khanna, G; Kumar, V; Tripathi, CD | 1 |
| Duncan, M; Parker, LA; Rock, EM; Sticht, MA; Stott, C | 1 |
| Bottegoni, G; Limebeer, CL; O'Brien, LD; Parker, LA; Piomelli, D; Rock, EM | 1 |
| Basavarajappa, BS; Subbanna, S | 1 |
| Aley-Medina, P; Anaya-Martínez, V; Avila-Costa, MR; Espinosa-Villanueva, J; García-Ruiz, R; Gutiérrez-Valdez, AL; Montiel-Flores, E; Reynoso-Erazo, L; Sánchez-Betancourt, J; Torres-Esquivel, C; Tron-Alvarez, R | 1 |
| Armentero, MT; Baqi, Y; Bonaventura, J; Canela, EI; Casadó, V; Cortés, A; Costa, G; Farré, D; Franco, R; Lanciego, JL; Lluís, C; Mallol, J; Martínez-Pinilla, E; McCormick, P; Müller, CE; Pinna, A; Sánchez, M; Simola, N | 1 |
| Abílio, VC; Almeida, V; Calzavara, MB; Crippa, JA; Hallak, JE; Levin, R; Peres, FF; Suiama, MA; Zuardi, AW | 1 |
| Ambrosi, G; Antoninetti, GF; Armentero, MT; Baqi, Y; Blandini, F; Cerri, S; Franco, R; Lanciego, JL; Levandis, G; Montepeloso, E; Müller, CE; Pinna, A | 1 |
| Busanello, A; de Freitas, CM; de Moraes Reis, E; Fachinetto, R; Ferreira, J; Figueira, FH; Leal, CQ; Mello, CF; Röpke, J; Villarinho, JG | 1 |
| Aveta, T; Borrelli, F; Buono, L; Capasso, R; Di Marzo, V; Izzo, AA; Orlando, P; Pagano, E | 1 |
| Bauer, R; Brodhun, M; Brust, P; Deuther-Conrad, W; Donat, CK; Fischer, F; Walter, B | 1 |
| Blasio, A; Cottone, P; Rice, KC; Sabino, V | 1 |
| Bogdanovic, RM; Jafari, M; Potschka, H; von Rüden, EL; Wotjak, CT | 1 |
| Benyhe, S; Borsodi, A; Csibrány, B; Klivényi, P; Lénárt, N; Marton, A; Molnár, M; Nagy, GM; Páldy, E; Samavati, R; Sántha, M; Tuka, B; Vécsei, L; Vizler, C; Zádor, F | 1 |
| Arlt, H; Augé, F; Avenet, P; Beeské, S; Bergis, OE; Bert, L; Bertrand, T; Brittain, S; Didier, M; Escoubet, J; Even, L; Françon, D; George, P; Griebel, G; He, T; Houtmann, J; Jacquet, A; Leroy, T; Lopez-Grancha, M; Menet, V; Michot, N; Mikol, V; Pichat, P; Rak, A; Redon, N; Sun, F; Tolstykh, T; Vallée, F; Wiederschain, D; Yu, Q; Zhang, B | 1 |
| Azzarone, B; Beaudreuil, S; Charpentier, B; Chatziantoniou, C; Dalia, M; Desterke, C; Devocelle, A; Durrbach, A; Ferlicot, S; François, H; Giron-Michel, J; Grassin-Delyle, S; Ivanovski, N; Lecru, L; Ledent, C; Saïd, M; Vandermeersch, S; Vazquez, A; Vernochet, A | 1 |
| Järbe, TU; Makriyannis, A; Nikas, SP; Shukla, VG; Tai, S; Vemuri, K | 1 |
| Markert, A; Nozaki, C; Zimmer, A | 1 |
| Bharne, AP; Borkar, CD; Kokare, DM; Subhedar, NK | 1 |
| Dragutinović, V; Ješić Vukićević, R; Jorgačević, B; Mladenović, D; Ninković, M; Radosavljević, T; Vatazević, A; Vesković, M; Vučević, D | 1 |
| Feleder, C; Gertzberg, N; James, J; Johnson, A; MacDonald, H; Neumann, PH; Peng, J; Russo, V | 1 |
| Li, H; Reichenbach, ZW; Tuma, RF; Ward, SJ | 1 |
| Antoniou, K; Delis, F; Gueye, AB; Laviolette, SR; Le Foll, B; Loureiro, M; Makriyannis, A; Poulia, N; Pryslawsky, Y; Trigo, JM; Vemuri, K | 1 |
| Di, S; Fisher, MO; Gilpin, NW; Itoga, CA; Roltsch, EA; Solomonow, J; Tasker, JG | 1 |
| Anderson, C; DiBerto, J; Duffy, K; Falls, WA; Fox, JH; Hammack, SE; Hardaway, JA; Hurd, YL; Kash, TL; Magness, ST; Mazzone, CM; McElligott, ZA; McKlveen, JM; Michaelides, M; Pati, D; Tipton, G | 1 |
| Cooper, TB; Hungund, BL; Thanos, PK; Vadasz, C; Vinod, KY; Volkow, ND; Yalamanchili, R | 1 |
| Fang, Q; Li, D; Li, F; Liu, Y; Lu, L; Wang, J; Zhao, M | 1 |
| Bennetzen, MF; Nielsen, MP; Pedersen, SB; Richelsen, B | 1 |
| Atkinson, RD; DeLeve, LD; Kanel, GC; McCuskey, RS; Wang, X | 1 |
| Hyytiä, P; Malinen, H | 1 |
| Di Marzo, V | 1 |
| Chou, CM; Samaha, FF | 1 |
| Chu, KL; Dart, MJ; McGaraughty, S; Meyer, MD; Yao, BB | 1 |
| Bagetta, G; Mannaioni, G; Pellegrini-Giampietro, DE | 1 |
| Hasenöhrl, RU; Ledent, C; Molleman, A; Thiemann, G; Watt, CA | 1 |
| Galzin, AM; Guillot, E; Lacombe, A; Lefèvre, AL; Magnan, C; Migrenne, S; Pruniaux, MP | 1 |
| Armstrong, C; Echegoyen, J; Morgan, RJ; Soltesz, I | 1 |
| Cassin, J; Harris, O; Kelsey, JE | 1 |
| Alvarez de Sotomayor, M; Callejón Mochón, M; Casto, C; Herrera, MD; Jiménez-Palacios, FJ; Marhuenda, E; Mingorance, C | 1 |
| Dykstra, LA; Rosenberg, M; Walker, EA; Ward, SJ | 1 |
| Immenschuh, S | 1 |
| Berrendero, F; Burokas, A; Gispert, JD; Heyne, A; Kiesselbach, C; Maldonado, R; Martín, M; Martín-García, E; Millán, O; Rubí, B | 1 |
| Goonawardena, AV; Hampson, RE; Pertwee, R; Platt, B; Riedel, G; Robinson, L | 1 |
| Bevan, SA; Hill, AJ; Jones, NA; Smith, I; Stephens, GJ; Weston, SE; Whalley, BJ; Williams, CM; Williamson, EM | 1 |
| Carai, MA; Colombo, G; Maccioni, P | 1 |
| Adler, M; Baty, DE; Ganea, D; Gaughan, J; Heller, JE; Jallo, JI; Li, H; Loftus, CM; Tuma, RF; Zhang, M | 1 |
| Abdullah, RA; Dewey, WL; Hoot, MR; Poklis, JL; Scoggins, KL; Selley, DE; Sim-Selley, LJ | 1 |
| Beyer, CE; Bingham, B; Chan, K; Dwyer, JM; Kennedy, JD; Manners, MT; Piesla, MJ; Platt, BJ; Rahman, Z; Samad, TA; Shen, R; Whiteside, GT | 1 |
| Baek, HS; Jin, HY; Liu, WJ; Park, JH; Park, TS | 1 |
| Diane, A; Kelly, SE; Mangat, R; Novak, S; Proctor, SD; Russell, JC; Vine, DF; Wang, Y | 1 |
| Bátkai, S; Gao, B; Harvey-White, J; Haskó, G; Mackie, K; Mukhopadhyay, B; Mukhopadhyay, P; Pacher, P; Pan, H; Patel, V; Rajesh, M | 1 |
| Dudek, FE; Pouliot, WA; Rossi, CA; Staley, KJ | 1 |
| Bäckhed, F; Cani, PD; Delzenne, NM; Lambert, DM; Muccioli, GG; Naslain, D; Reigstad, CS | 1 |
| Calignano, A; Clapper, JR; Duranti, A; Guijarro, A; Hohmann, AG; Mor, M; Moreno-Sanz, G; Piomelli, D; Russo, R; Sanchini, S; Sciolino, NR; Spradley, JM; Tarzia, G; Tontini, A; Vacondio, F | 1 |
| Ballantyne, CM; Mansoori, A; Perrard, JL; Perrard, XD; Smith, CW; Wang, Q; Wu, H | 1 |
| Dowd, E; Finn, DP; Gorman, AM; Walsh, S | 1 |
| Cabasino, S; Lazzari, P; Manca, I; Mastinu, A; Pani, L; Sanna, A | 1 |
| Cravatt, BF; Kinsey, SG; Lichtman, AH; Long, JZ; O'Neal, ST | 1 |
| Carai, MA; Colombo, G; Cooper, TB; Femenia, T; Garcia-Gutierrez, MS; Hungund, BL; Maccioni, P; Manzanares, J; Vinod, KY; Xie, S | 1 |
| Conrad, DH; Lichtman, AH; O'Neal, ST; Schlosburg, JE | 1 |
| Dykstra, LA; Miller, LL; Picker, MJ; Schmidt, KT | 1 |
| Aouad, L; Bell-Anderson, KS; Caterson, ID; Farrell, GC; Larter, CZ; Phuyal, J; Sanz, FR; Williams, H | 1 |
| Perescis, MF; van Luijtelaar, G; van Rijn, CM; Vinogradova, L | 1 |
| Almeida, MC; Balaskó, M; Dogan, MD; Eales, J; Gavva, NR; Molchanova, AY; Oliveira, DL; Patel, S; Pétervári, E; Romanovsky, AA; Steiner, AA; Székely, M; Wanner, SP | 1 |
| Alhouayek, M; Cani, PD; Delzenne, NM; Lambert, DM; Muccioli, GG | 1 |
| Shatskova, AB; van Rijn, CM; Vinogradova, LV | 1 |
| Lou, ZY; Xiao, BG; Zhao, CB | 1 |
| Degrace, P; Demizieux, L; Djaouti, L; Gaba, L; Gresti, J; Jourdan, T; Vergès, B | 1 |
| Boomhower, SR; Buckley, J; Rasmussen, EB; Reilly, W | 1 |
| Antunes-Rodrigues, J; de Carvalho Borges, B; Elias, LL; Reis, WL; Rorato, R | 1 |
| Baldassarre, M; Bernardi, M; Caraceni, P; Domenicali, M; Giannone, FA; Trevisani, F; Zaccherini, G | 1 |
| Bergman, RN; Catalano, KJ; Chiu, JD; Harrison, LN; Hsu, IR; Ionut, V; Kabir, M; Kim, SP; Kolka, C; Lottati, M; Richey, JM; Stefanoski, D; Woolcott, OO; Zheng, D | 1 |
| Bellini, G; Boccella, S; de Novellis, V; Guida, F; Luongo, L; Maione, S; Marabese, I; Palazzo, E; Rossi, F | 1 |
| Cheer, JF; Glick, SD; Morra, JT | 1 |
| Elbatsh, MM; Kendall, DA; Marsden, CA; Moklas, MA | 1 |
| Abílio, VC; Almeida, V; Calzavara, MB; Crippa, JA; da Silva, ND; Hallak, JE; Levin, R; Niigaki, ST; Peres, FF; Suiama, MA; Zuardi, AW | 1 |
| Abou-El-Ela, SH; El-Wakeil, AF; Zaitone, SA | 1 |
| Lazzari, P; Mastinu, A; Pani, L; Pinna, GA; Pira, M | 1 |
| Gyertyán, I; Kassai, F; Varga, B | 1 |
| Businco, F; Dessi, C; Fadda, P; Fattore, L; Fratta, W; Goldberg, SR; Pigliacampo, B; Satta, V; Scherma, M | 1 |
| Dashney, B; Limebeer, CL; O'Brien, LD; Parker, LA; Rock, EM; Segsworth, B; Wills, KL | 1 |
| Aguiar, DC; Campos, AC; Díaz-Alonso, J; Fogaça, MV; Galve-Roperh, I; Guimarães, FS; Guzmán, M; Moreira, FA; Ortega, Z; Ortega-Gutiérrez, S; Palazuelos, J; Vázquez-Villa, H | 1 |
| Löscher, W; Richter, A | 1 |
| Abbott, L; Burton, P; Fudge, ML; Mechoulam, R; Parker, LA; Schlievert, C | 1 |
| de Miguel, R; De Petrocellis, L; Di Marzo, V; Fernández-Ruiz, J; Lastres-Becker, I; Makriyannis, A | 1 |
| Hohmann, AG; Nackley, AG; Suplita, RL | 1 |
| Bensaid, M; Esclangon, A; Gary-Bobo, M; Le Fur, G; Maffrand, JP; Oury-Donat, F; Soubrié, P | 1 |
| Niederhoffer, N; Schmid, K; Szabo, B | 1 |
| Croft, DL; Hamamoto, DT; Kehl, LJ; Norsted, BD; Simone, DA; Wacnik, PW; Wilcox, GL | 1 |
| Hohmann, AG; Makriyannis, A; Nackley, AG | 1 |
| Fernández-Frutos, B; González, R; Martínez-Orgado, J; Romero, E; Romero, J; Urigüen, L; Viveros, MP | 1 |
| Bizat, N; Boyer, F; Brouillet, E; Fernández-Ruiz, J; Hantraye, P; Lastres-Becker, I | 1 |
| Asbrock, N; Ferrer, B; Giuffrida, A; Kathuria, S; Piomelli, D | 1 |
| Berger, C; Schabitz, WR; Schmid, HH; Schmid, PC; Schwab, S; Wolf, M | 1 |
| Godlewski, G; Malinowska, B; Schlicker, E | 1 |
| Caraballo, I; El-Banoua, F; Fernandez-Espejo, E; Flores, JA; Galan-Rodriguez, B | 1 |
| Abood, ME; McAllister, SD; Moore, DH; Patel, SG; Raman, C; Rizvi, G | 1 |
| Abe, T; Arisaka, O; Morimoto, H; Yamada, Y; Yoshihara, S | 1 |
| Colleoni, M; Costa, B; Franke, C; Giagnoni, G; Trovato, AE | 1 |
| Cascio, MG; Di Marzo, V; Parolaro, D; Rubino, T; Valenti, M; Viganò, D | 1 |
| Chapman, V; Elmes, SJ; Jhaveri, MD; Kendall, DA; Smart, D | 1 |
| Gross, GJ; Hillard, CJ; Muthian, S; Rademacher, DJ; Roelke, CT | 1 |
| Abe, K; Egashira, N; Fujiwara, M; Hasebe, N; Hayakawa, K; Ikeda, T; Inui, K; Iwasaki, K; Mishima, K; Takamatsu, F; Yasuda, H | 1 |
| De Vries, TJ; Schoffelmeer, AN | 1 |
| Adrian, R; Baratta, J; Giuffrida, A; Piomelli, D; Solbrig, MV | 1 |
| Beardsley, PM; Thomas, BF | 1 |
| de Miguel, R; Fernández-Ruiz, J; García-Arencibia, M; González, S; Ramos, JA; Scorticati, C | 1 |
| Bortolato, M; Calignano, A; Campolongo, P; Cuomo, V; Frau, R; Gessa, GL; La Rana, G; Mangieri, RA; Piomelli, D; Russo, R; Scattoni, ML; Trezza, V | 1 |
| Cossu, G; Deiana, S; Fadda, P; Fattore, L; Fratta, W; Melis, V; Spano, MS | 1 |
| Fernández-López, D; Lizasoain, I; Lorenzo, P; Martínez-Orgado, J; Moro, MA; Nuñez, E; Romero, J | 1 |
| Heal, DJ | 1 |
| de Novellis, V; Di Marzo, V; Giordano, C; Maione, S; Mangoni, GS; Marabese, I; Palazzo, E; Petrosino, S; Rossi, F; Vita, D | 1 |
| Blair, RE; Carter, DS; DeLorenzo, RJ; Deshpande, LS; Martin, BR; Sombati, S | 1 |
| De Witte, P; Lallemand, F | 1 |
| Adler, MW; Benamar, K; Eisenstein, TK; Geller, EB; Meissler, JJ; Tallarida, RJ; Yondorf, M | 1 |
| Ballmaier, M; Bortolato, M; Gessa, G; Heinz, A; Rizzetti, C; Spano, P; Zoli, M | 1 |
| Deveaux, V; Hezode, C; Lotersztajn, S; Mallat, A; Teixeira-Clerc, F; Tran van Nhieu, J | 1 |
| Abe, K; Egashira, N; Fujioka, M; Fujiwara, M; Hasebe, N; Hayakawa, K; Hazekawa, M; Irie, K; Iwasaki, K; Mishima, K; Nozako, M; Orito, K | 1 |
| Del Arco, I; Javier Pavón, F; Macías, M; Perez-Valero, V; Rodríguez de Fonseca, F; Serrano, A | 1 |
| Buettner, R; Cravatt, B; Date, R; Di Marzo, V; Gaffal, E; Karsak, M; Mechoulam, R; Petrosino, S; Rehnelt, J; Schlicker, E; Starowicz, K; Steuder, R; Tüting, T; Wang-Eckhardt, L; Werner, S; Zimmer, A | 1 |
| Advenier, C; Chen, HZ; Cui, YY; D'Agostino, B; Finance, O; Marrocco, G; Naline, E; Rinaldi-Carmona, M; Risse, PA; Rossi, F; Zhang, Y | 1 |
| Abood, ME; Gehani, NC; Hough, LB; Martin, BR; Nalwalk, JW; Razdan, RK; Sun, X; Wentland, M | 1 |
| Bettoni, I; Colleoni, M; Comelli, F; Costa, B; Giagnoni, G | 1 |
| Kaiser, N; Lutz, B; Monory, K; Moreira, FA | 1 |
| Barbosa, I; Bidouard, JP; Cadrouvele, C; Dedio, J; Gouraud, L; Herbert, JM; Janiak, P; Le Fur, G; Maffrand, JP; O'Connor, S; Pierre, F; Poirier, B | 1 |
| Holsboer, F; Lutz, B; Marsicano, G; Nestler, EJ; Steiner, MA; Wotjak, CT | 1 |
| Alvarez-Jaimes, L; Parsons, LH; Polis, I | 1 |
| Goldberg, SR; Justinova, Z; Munzar, P; Panlilio, LV; Redhi, GH; Tanda, G; Yasar, S | 1 |
| Friedman, SL; Nieto, N | 1 |
| Bátkai, S; Gao, B; Harvey-White, J; Horiguchi, N; Jeong, WI; Kunos, G; Liu, J; Lutz, B; Marsicano, G; Mukhopadhyay, P; Osei-Hyiaman, D; Park, O | 1 |
| Di Marzo, V; Szallasi, A | 1 |
| Aviello, G; Borrelli, F; Capasso, F; Capasso, R; Izzo, AA; Romano, B; Scalisi, C | 1 |
| Bauersachs, J; Ertl, G; Fiedler, S; Neumüller, J; Pfrang, J; Schäfer, A | 1 |
| Baker, D; Brown, P; Croxford, JL; Huffman, JW; Layward, L; Pertwee, RG; Pryce, G | 1 |
| Massi, P; Parolaro, D; Rubino, T; Viganò, D | 1 |
| Cossu, G; Fattore, L; Fratta, W; Martellotta, MC; Mascia, MS | 1 |
| Baker, D; Bisogno, T; Brown, P; Croxford, JL; Di Marzo , V; Fezza, F; Khanolkar, A; Layward, L; Makriyannis, A; Pertwee, RG; Pryce, G | 1 |
| Davydova, YG; Maimeskulova, LA; Mechoulam, R; Ugdyzhekova, DS | 1 |
| Fox, A; Gentry, C; James, I; Kesingland, A; McNair, K; Patel, S; Urban, L | 1 |
| Ahmad, K; Bridges, D; Rice, AS | 1 |
| Carrera, MR; Chowen, JA; Cossu, G; del Arco, I; Fattore, L; Fratta, W; Gomez, R; Koob, GF; Maldonado, R; Navarro, M; Rodriguez de Fonseca, F; Valverde, O; Villanua, MA | 1 |
| Azami, J; Green, DL; Monhemius, R; Roberts, MH | 1 |
| Rice, AS | 1 |
| Bardotti, M; Parolaro, D; Poli, G; Ponti, W; Rubino, T | 1 |
| Bisogno, T; Capasso, F; Capasso, R; Di Marzo, V; Esposito, G; Fezza, F; Iuvone, T; Izzo, AA; Mascolo, N; Pinto, L | 1 |
| Piomelli, D | 1 |
| Crombag, H; De Vries, TJ; Dieben, J; Homberg, JR; Schoffelmeer, AN; Schuurman, K; Shaham, Y; Vanderschuren, LJ | 1 |
| Bar, PR; Bisogno, T; Di Marzo, V; Fezza, F; Nicolay, K; van der Stelt, M; van Haaften, GW; Veldhuis, WB; Veldink, GA; Vliegenthart, JF | 1 |
| Baker, D; Bifulco, M; Bisogno, T; Bridges, D; Brooks, JW; Brown, P; Di Marzo, V; Hankey, DJ; Jaggar, SI; Ledent, C; Pryce, G; Rice, AS | 1 |
8 review(s) available for sr141716 and Disease Models, Animal
| Article | Year |
|---|---|
CB(1) receptor antagonism: biological basis for metabolic effects.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Drug Delivery Systems; Gene Expression Regulation; Homeostasis; Humans; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |
Blockade of the endocannabinoid system for the reduction of cardiometabolic risk factors.
Topics: Animals; Cannabinoid Receptor Modulators; Cardiovascular Diseases; Disease Models, Animal; Endocannabinoids; Energy Metabolism; Humans; Mice; Obesity; Piperidines; Pyrazoles; Rats; Rimonabant; Risk Factors | 2009 |
Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death.
Topics: Animals; Brain Injuries; Brain Ischemia; Cannabinoid Receptor Modulators; Cell Death; Disease Models, Animal; Endocannabinoids; Humans; Ischemic Attack, Transient; Isoenzymes; Neurons; Nitric Oxide Synthase; Piperidines; Pyrazoles; Rimonabant | 2009 |
Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data.
Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Animals; Brain; Cannabinoid Receptor Modulators; Cannabinoids; Disease Models, Animal; Humans; Models, Animal; Narcotic Antagonists; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
Cannabinoid CB1 receptors control conditioned drug seeking.
Topics: Animals; Conditioning, Psychological; Disease Models, Animal; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Substance-Related Disorders | 2005 |
Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders.
Topics: Animals; Disease Models, Animal; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance-Related Disorders | 2005 |
An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives.
Topics: Animals; Brain; Cannabinoid Receptor Modulators; Disease Models, Animal; Endocannabinoids; Humans; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Reward; Rimonabant; Secondary Prevention; Substance Withdrawal Syndrome; Substance-Related Disorders | 2007 |
Cannabinoids and pain.
Topics: Amides; Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Benzoxazines; Brain; Camphanes; Cannabinoid Receptor Modulators; Cannabinoids; Cell Membrane; Clinical Trials as Topic; Disease Models, Animal; Drug Design; Drug Interactions; Endocannabinoids; Enzyme Inhibitors; Ethanolamines; Glycerides; Humans; Injections, Spinal; Molecular Structure; Morpholines; Naphthalenes; Pain; Palmitates; Palmitic Acids; Piperidines; Plant Extracts; Polyunsaturated Alkamides; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Spinal Cord | 2001 |
172 other study(ies) available for sr141716 and Disease Models, Animal
| Article | Year |
|---|---|
Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists.
Topics: Animals; Area Under Curve; Binding, Competitive; Body Weight; Disease Models, Animal; Drug Evaluation, Preclinical; Eating; Humans; Imidazoles; Molecular Structure; Obesity; Rats; Receptor, Cannabinoid, CB1; Structure-Activity Relationship | 2005 |
Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding, Competitive; Cell Line; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Hyperalgesia; Indoles; Ketones; Ligands; Molecular Conformation; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Stereoisomerism; Structure-Activity Relationship | 2008 |
Benzodioxoles: novel cannabinoid-1 receptor inverse agonists for the treatment of obesity.
Topics: Animals; Anti-Obesity Agents; Benzodioxoles; Body Weight; Crystallography, X-Ray; Cyclohexanols; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Hypothermia; Ligands; Male; Mice; Microsomes; Models, Molecular; Molecular Structure; Obesity; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Structure-Activity Relationship | 2008 |
Aminopyrazine CB1 receptor inverse agonists.
Topics: Animals; Blood Glucose; Combinatorial Chemistry Techniques; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Feeding Behavior; Humans; Microsomes, Liver; Molecular Structure; Obesity; Piperidines; Pyrazines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rimonabant; Structure-Activity Relationship | 2008 |
Novel thioamide derivatives as neutral CB1 receptor antagonists.
Topics: Animals; Anti-Obesity Agents; Disease Models, Animal; Mice; Mice, Obese; Obesity; Pyrazines; Receptor, Cannabinoid, CB1; Structure-Activity Relationship; Thioamides | 2010 |
Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern.
Topics: Administration, Oral; Aminoimidazole Carboxamide; Animals; Disease Models, Animal; Drug Inverse Agonism; Hypotension; Imidazoles; Mice; Rats; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Sulfones | 2010 |
Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Ligands; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Multiple Sclerosis; Quantitative Structure-Activity Relationship; Quinolines; Receptor, Cannabinoid, CB2 | 2015 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Rimonabant ameliorates hepatic ischemia/reperfusion injury in rats: Involvement of autophagy via modulating ERK- and PI3K/AKT-mTOR pathways.
Topics: Animals; Autophagy; Autophagy-Related Proteins; Cannabinoid Receptor Antagonists; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Hepatitis; Inflammation Mediators; Lipid Peroxidation; Liver; Liver Cirrhosis; Male; Oxidative Stress; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Rats, Wistar; Receptor, Cannabinoid, CB1; Reperfusion Injury; Rimonabant; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Treadmill exercise modulates nigral and hippocampal cannabinoid receptor type 1 in the 6-OHDA model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Drug Inverse Agonism; Hippocampus; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Wistar; Receptors, Cannabinoid; Rimonabant; Substantia Nigra | 2023 |
Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity.
Topics: Animals; Disease Models, Animal; Edema; Feeding Behavior; Indazoles; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Mice; Molecular Structure; Rats; Receptors, Cannabinoid; Rimonabant; Valine; Zymosan | 2019 |
The analgesic effect of refeeding on acute and chronic inflammatory pain.
Topics: Acute Pain; Analgesics, Opioid; Animals; Chronic Pain; Disease Models, Animal; Eating; Food Deprivation; Formaldehyde; Freund's Adjuvant; Glucose; Hot Temperature; Hyperalgesia; Inflammation; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Naloxone; Narcotic Antagonists; Pain Management; Pain Measurement; Rimonabant | 2019 |
CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced bone metabolism disorder and destruction in rats.
Topics: Animals; Bone Diseases, Metabolic; Cannabinoid Receptor Antagonists; Disease Models, Animal; Hypoxia; Male; Osteoclasts; Protective Agents; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Tartrate-Resistant Acid Phosphatase | 2020 |
Subchronic Central Administration of Cannabinoid Ligands Modulates Nociception in Bulbectomized Rats.
Topics: Animals; Depression; Disease Models, Animal; Dronabinol; Ligands; Male; Nociception; Olfactory Bulb; Pain Threshold; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant | 2019 |
Subchronic effects of ligands of cannabinoid receptors on learning and memory processes of olfactory bulbectomized rats.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Learning; Male; Memory; Memory Disorders; Rats, Wistar; Receptors, Cannabinoid; Rimonabant | 2020 |
CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced renal injury in rats.
Topics: Animals; Disease Models, Animal; Hypoxia; Kidney Tubules; Male; Membrane Proteins; Mitochondria; Mitochondrial Proteins; Random Allocation; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Renal Insufficiency, Chronic; Rimonabant; Sleep Apnea, Obstructive; Src Homology 2 Domain-Containing, Transforming Protein 1 | 2021 |
Cannabinoid-Induced Tetrad in Mice.
Topics: Animals; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Catalepsy; Disease Models, Animal; Dronabinol; Exploratory Behavior; Hypothermia; Male; Mice; Mice, Inbred C57BL; Movement Disorders; Piperidines; Pyrazoles; Rimonabant | 2017 |
Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin.
Topics: Activins; Animals; Biomarkers; Cannabinoid Receptor Antagonists; Cytoprotection; Disease Models, Animal; Follistatin; Gene Expression Regulation; Liver; Male; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Transforming Growth Factor beta | 2017 |
Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer.
Topics: Animals; Cannabinoid Receptor Antagonists; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Disease Models, Animal; Female; Heterografts; Histone Acetyltransferases; Humans; Mice, SCID; Models, Biological; Neoplasm Transplantation; Rimonabant; Treatment Outcome; Wnt Signaling Pathway | 2017 |
The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice.
Topics: Amines; Analgesics; Animals; Benzodioxoles; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Tolerance; Enzyme Inhibitors; Gabapentin; gamma-Aminobutyric Acid; Hyperalgesia; Male; Mice; Mice, Inbred C57BL; Monoacylglycerol Lipases; Neuralgia; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction | 2017 |
Neuroprotective effect of cannabinoid receptor 1 antagonist in the MNU-induced retinal degeneration model.
Topics: Alkylating Agents; Animals; Biomarkers; Blotting, Western; Cannabinoid Receptor Antagonists; Disease Models, Animal; Fluorescent Antibody Technique, Indirect; Methylnitrosourea; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Patch-Clamp Techniques; Photoreceptor Cells, Vertebrate; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Retina; Retinal Degeneration; Rimonabant | 2018 |
Role of the endogenous cannabinoid receptor 1 in brain injury induced by chronic intermittent hypoxia in rats.
Topics: Animals; Brain Injuries; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cannabinoid Receptor Antagonists; Chronic Disease; Disease Models, Animal; Gene Expression Regulation; Hippocampus; Hypoxia; Male; Piperidines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rimonabant | 2018 |
Effects of repeated long-term psychosocial stress and acute cannabinoid exposure on mouse corticostriatal circuitries: Implications for neuropsychiatric disorders.
Topics: Animals; Body Weight; Cannabinoid Receptor Antagonists; Cannabinoids; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Exploratory Behavior; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; Neural Pathways; Rimonabant; RNA, Messenger; Stress, Psychological; Tacrolimus Binding Proteins; Tirapazamine | 2018 |
Neuronal nicotinic acetylcholine receptors mediate ∆
Topics: Animals; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dronabinol; Humans; Marijuana Abuse; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, Nicotinic; Rimonabant; Substance Withdrawal Syndrome | 2020 |
The effect of cannabinoid receptor 1 blockade on adipokine and proinflammatory cytokine concentration in adipose and hepatic tissue in mice with nonalcoholic fatty liver disease.
Topics: Adipokines; Adipose Tissue; Animals; Blood Glucose; Cannabinoid Receptor Antagonists; Cytokines; Diet, High-Fat; Disease Models, Animal; Drug Evaluation, Preclinical; Glucose; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Receptor, Cannabinoid, CB1; Rimonabant | 2019 |
Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome.
Topics: Animals; Brain; Cannabinoid Receptor Antagonists; Cognition; Cognitive Dysfunction; Disease Models, Animal; Down Syndrome; Female; Male; Mice; Mice, Transgenic; Neurogenesis; Phenotype; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2019 |
Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments.
Topics: Administration, Intravenous; Animals; Disease Models, Animal; Dronabinol; Drug Tolerance; Female; Hallucinogens; Humans; Macaca mulatta; Male; Motor Activity; Rimonabant; Substance Withdrawal Syndrome | 2019 |
Hedonic drinking engages a supraspinal inhibition of thermal nociception in adult rats.
Topics: Animals; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Drinking Behavior; Freund's Adjuvant; Hot Temperature; Hyperalgesia; Injections, Spinal; Male; Naloxone; Narcotic Antagonists; Pain Threshold; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Reaction Time; Rimonabant; Spinal Cord; Sucrose; Sweetening Agents; Water Deprivation | 2019 |
A translational rodent assay of affective biases in depression and antidepressant therapy.
Topics: Affect; Animals; Antidepressive Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Carbolines; Depression; Discrimination Learning; Disease Models, Animal; Environment; Isotretinoin; Male; Piperidines; Pyrazoles; Rats; Reward; Rimonabant; Stress, Psychological; Translational Research, Biomedical | 2013 |
Synergic insulin sensitizing effect of rimonabant and BGP-15 in Zucker-obese rats.
Topics: Analysis of Variance; Animals; Blood Glucose; Disease Models, Animal; Drug Synergism; Glucose; Glucose Clamp Technique; Hyperinsulinism; Insulin; Insulin Resistance; Male; Obesity; Oximes; Piperidines; Pyrazoles; Rats; Rats, Zucker; Rimonabant | 2013 |
Anti-obesity effect of Gymnema sylvestre extract on high fat diet-induced obesity in Wistar rats.
Topics: Animals; Anti-Obesity Agents; Antioxidants; Diet, High-Fat; Disease Models, Animal; Gymnema sylvestre; Male; Medicine, Ayurvedic; Obesity; Piperidines; Plant Extracts; Pyrazoles; Rats; Rats, Wistar; Rimonabant | 2013 |
Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
Topics: Animals; Behavior, Animal; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Dronabinol; Drug Partial Agonism; Lithium Chloride; Male; Nausea; Phytochemicals; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2013 |
Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus).
Topics: Amidohydrolases; Animals; Antiemetics; Arachidonic Acids; Behavior, Animal; Biological Transport; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Endocannabinoids; Isoenzymes; Lithium Chloride; Male; Nausea; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Shrews; Vomiting | 2013 |
CB1 receptor-mediated signaling underlies the hippocampal synaptic, learning, and memory deficits following treatment with JWH-081, a new component of spice/K2 preparations.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 4; Cannabinoid Receptor Antagonists; Cannabinoids; CREB-Binding Protein; Disease Models, Animal; Dose-Response Relationship, Drug; Hippocampus; Indoles; Learning Disabilities; Long-Term Potentiation; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Knockout; Naphthalenes; Phosphorylation; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Space Perception; Synapses | 2014 |
The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Topics: Administration, Oral; Animals; Cannabinoid Receptor Antagonists; Corpus Striatum; Dihydroxyphenylalanine; Disease Models, Animal; Dopamine Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Male; Nerve Degeneration; Neuropil; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rimonabant; Substantia Nigra; Tyrosine 3-Monooxygenase | 2013 |
L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Cannabinoid Receptor Antagonists; Cholinesterase Inhibitors; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Interactions; Functional Laterality; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Rimonabant; Tacrine; Time Factors; Tremor | 2014 |
Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: the SHR strain.
Topics: Analysis of Variance; Animals; Arachidonic Acids; Benzoxazines; Cannabinoid Receptor Modulators; Capsaicin; Disease Models, Animal; Dose-Response Relationship, Drug; Interpersonal Relations; Male; Morpholines; Motor Activity; Naphthalenes; Piperidines; Pyrazoles; Rats; Rats, Inbred SHR; Rats, Wistar; Rimonabant; Schizophrenia; Schizophrenic Psychology; TRPV Cation Channels | 2014 |
Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Cannabinoid Receptor Antagonists; Disease Models, Animal; Male; Neuroprotective Agents; Parkinson Disease; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Xanthines | 2014 |
Anandamide attenuates haloperidol-induced vacuous chewing movements in rats.
Topics: Animals; Antipsychotic Agents; Arachidonic Acids; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Endocannabinoids; Haloperidol; Male; Mastication; Movement; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Treatment Outcome | 2014 |
Palmitoylethanolamide normalizes intestinal motility in a model of post-inflammatory accelerated transit: involvement of CB₁ receptors and TRPV1 channels.
Topics: Amides; Animals; Colitis; Disease Models, Animal; Ethanolamines; Gastrointestinal Motility; Inflammation; Injections, Intraperitoneal; Irritable Bowel Syndrome; Male; Mice; Mice, Inbred ICR; Mustard Plant; Palmitic Acids; Piperidines; Plant Oils; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; TRPV Cation Channels | 2014 |
Early increase of cannabinoid receptor density after experimental traumatic brain injury in the newborn piglet.
Topics: Analysis of Variance; Animals; Animals, Newborn; Autoradiography; Brain; Brain Injuries; Cannabinoid Receptor Modulators; Cyclohexanols; Disease Models, Animal; Female; Isoquinolines; Piperidines; Protein Binding; Pyrazoles; Radionuclide Imaging; Receptors, Cannabinoid; Receptors, GABA; Rimonabant; Swine; Time Factors; Tritium | 2014 |
Characterization of a shortened model of diet alternation in female rats: effects of the CB1 receptor antagonist rimonabant on food intake and anxiety-like behavior.
Topics: Animals; Anxiety; Behavior, Animal; Cannabinoid Receptor Antagonists; Dietary Sucrose; Disease Models, Animal; Dose-Response Relationship, Drug; Eating; Feeding and Eating Disorders; Female; Maze Learning; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant | 2014 |
Analysis in conditional cannabinoid 1 receptor-knockout mice reveals neuronal subpopulation-specific effects on epileptogenesis in the kindling paradigm.
Topics: Anilides; Animals; Bromodeoxyuridine; Calcium-Calmodulin-Dependent Protein Kinase Type 1; Cannabinoid Receptor Antagonists; Cinnamates; Disease Models, Animal; Epilepsy; gamma-Aminobutyric Acid; Gene Expression Regulation; Kindling, Neurologic; Male; Mice; Mice, Knockout; Neurogenesis; Neurons; Piperidines; Prosencephalon; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; TRPV Cation Channels | 2015 |
Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
Topics: Adaptation, Ocular; Analgesics, Opioid; Animals; Anxiety; Cannabinoid Receptor Antagonists; CHO Cells; Cricetulus; Disease Models, Animal; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Knockout; Narcotic Antagonists; Piperidines; Prosencephalon; Protein Binding; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Opioid, kappa; Rimonabant; Swimming | 2015 |
Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents.
Topics: Acetylcholine; Administration, Oral; Analgesics; Animals; Arachidonic Acids; Binding Sites; Brain; Cannabinoid Receptor Antagonists; Carbamates; Chromatography, High Pressure Liquid; Crystallography, X-Ray; Disease Models, Animal; Electric Stimulation; Endocannabinoids; Enzyme Inhibitors; Glycerides; Hippocampus; Humans; Hydrolysis; In Vitro Techniques; Learning; Long-Term Potentiation; Mass Spectrometry; Memory, Short-Term; Mice; Mice, Inbred C57BL; Mice, SCID; Monoacylglycerol Lipases; Pain; Piperidines; Protein Structure, Tertiary; Pyrazoles; Rimonabant; Seizures; Sulfonamides | 2015 |
Distinct Neuropsychological Mechanisms May Explain Delayed- Versus Rapid-Onset Antidepressant Efficacy.
Topics: Animals; Antidepressive Agents; Association Learning; Brain; Cannabinoid Receptor Antagonists; Carbolines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; GABA Antagonists; Ketamine; Male; Mood Disorders; Piperidines; Pyrazoles; Rats; Reaction Time; Reinforcement, Psychology; Rimonabant; Stress, Psychological; Venlafaxine Hydrochloride | 2015 |
Cannabinoid receptor 1 is a major mediator of renal fibrosis.
Topics: Acute Disease; Animals; Arachidonic Acids; Cells, Cultured; Chemokine CCL2; Collagen; Diabetes Mellitus; Disease Models, Animal; Endocannabinoids; Fibrosis; Gene Expression Profiling; Glomerulonephritis, IGA; Glycerides; Humans; Kidney; Ligands; Macrophages; Mice; Mice, Knockout; Myofibroblasts; Nephritis, Interstitial; Oligonucleotide Array Sequence Analysis; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; RNA, Messenger; Transforming Growth Factor beta1; Up-Regulation; Ureteral Obstruction | 2015 |
Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist.
Topics: Animals; Body Temperature; Cannabinoid Receptor Antagonists; Cannabinoids; Disease Models, Animal; Dronabinol; Drug Tolerance; Male; Mice; Morpholines; Motor Activity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Substance Withdrawal Syndrome | 2015 |
Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.
Topics: Amidohydrolases; Analgesics; Animals; Arachidonic Acids; Benzamides; Cannabinoid Receptor Antagonists; Carbamates; Disease Models, Animal; Dose-Response Relationship, Drug; Endocannabinoids; Enzyme Inhibitors; Hyperalgesia; Male; Mice, Inbred C57BL; Mice, Knockout; Migraine Disorders; Monoacylglycerol Lipases; Nitroglycerin; Pain Measurement; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Touch; Trigeminal Nuclei | 2015 |
Differential expression of CART in feeding and reward circuits in binge eating rat model.
Topics: Anhedonia; Animals; Binge-Eating Disorder; Brain; Cannabinoid Receptor Antagonists; Disease Models, Animal; Eating; Male; Nerve Tissue Proteins; Neural Pathways; Piperidines; Pyrazoles; Random Allocation; Rats, Wistar; Reward; Rimonabant; Satiation; Synaptophysin | 2015 |
Rimonabant Improves Oxidative/Nitrosative Stress in Mice with Nonalcoholic Fatty Liver Disease.
Topics: Animals; Cannabinoid Receptor Antagonists; Diet, High-Fat; Disease Models, Animal; Glutathione; Liver; Male; Malondialdehyde; Metals; Mice; Mice, Inbred C57BL; Nitrates; Nitrites; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Piperidines; Pyrazoles; Rimonabant; Superoxide Dismutase | 2015 |
The intracerebroventricular injection of rimonabant inhibits systemic lipopolysaccharide-induced lung inflammation.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Injections, Intraventricular; Lipopolysaccharides; Lung; Male; Peroxidase; Piperidines; Pneumonia; Pulmonary Edema; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant; Signal Transduction; Time Factors; Toll-Like Receptor 4 | 2015 |
The CB1 antagonist, SR141716A, is protective in permanent photothrombotic cerebral ischemia.
Topics: Animals; Behavior, Animal; Body Weight; Brain; Brain Ischemia; Cannabinoid Receptor Antagonists; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Stroke | 2016 |
The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.
Topics: Animals; Anxiety; Behavior, Addictive; Behavior, Animal; Cannabinoid Receptor Antagonists; Cues; Depression; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Drug Inverse Agonism; Drug-Seeking Behavior; Male; Maze Learning; Mesencephalon; Motivation; Motor Activity; Piperidines; Pyrazoles; Rats, Long-Evans; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Swimming; Time Factors; Tobacco Use Cessation Devices; Tobacco Use Disorder; Weight Loss | 2016 |
Acute Stress Suppresses Synaptic Inhibition and Increases Anxiety via Endocannabinoid Release in the Basolateral Amygdala.
Topics: Animals; Antiemetics; Anxiety; Arachidonic Acids; Basolateral Nuclear Complex; Benzoxazines; Calcium Channel Blockers; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Dexamethasone; Disease Models, Animal; Endocannabinoids; Enzyme Inhibitors; Glucocorticoids; Glycerides; Inhibitory Postsynaptic Potentials; Male; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Rats; Rats, Wistar; Restraint, Physical; Rimonabant; Synaptic Transmission | 2016 |
Acute engagement of G
Topics: Animals; Anti-Anxiety Agents; Anxiety; Brain Mapping; Cannabinoid Receptor Antagonists; Clozapine; Dark Adaptation; Disease Models, Animal; Estrenes; Excitatory Postsynaptic Potentials; Exploratory Behavior; Green Fluorescent Proteins; GTP-Binding Protein alpha Subunits, Gq-G11; In Vitro Techniques; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Phosphodiesterase Inhibitors; Piperazines; Pyrrolidinones; Receptors, Drug; Rimonabant; RNA, Messenger; Septal Nuclei; Serotonin Receptor Agonists; Signal Transduction; Sodium Channel Blockers; Tetrodotoxin; Vesicular Inhibitory Amino Acid Transport Proteins | 2018 |
Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice.
Topics: Alcohol-Induced Disorders, Nervous System; Alcoholism; Analgesics; Animals; Binding, Competitive; Brain; Cyclohexanols; Disease Models, Animal; Genetic Predisposition to Disease; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptors, G-Protein-Coupled; Rimonabant; Species Specificity | 2008 |
Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.
Topics: Animals; Behavior, Animal; Conditioning, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Extinction, Psychological; Injections, Intraperitoneal; Ketamine; Male; Piperidines; Psychotropic Drugs; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Recurrence; Rimonabant; Substance-Related Disorders | 2008 |
Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats.
Topics: Adiponectin; Animals; Body Weight; Cholesterol; Disease Models, Animal; Eating; Fatty Acids, Nonesterified; Glycerol; Lipids; Male; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Thinness; Triglycerides | 2008 |
Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis.
Topics: Actins; Animals; Apolipoprotein A-I; Body Weight; Cells, Cultured; Diet; Disease Models, Animal; Fatty Liver; Hepatocytes; Inflammation; Liver; Liver Cirrhosis; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Organ Size; Piperidines; Pyrazoles; Rimonabant | 2008 |
Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats.
Topics: Alcohol Drinking; Alcoholism; Animals; Benzoxazines; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Male; Microinjections; Morpholines; Naphthalenes; Nucleus Accumbens; Piperidines; Pyrazoles; Rats; Rats, Inbred Strains; Receptor, Cannabinoid, CB1; Reinforcement, Psychology; Rimonabant; Signal Transduction; Ventral Tegmental Area | 2008 |
A CB(2) receptor agonist, A-836339, modulates wide dynamic range neuronal activity in neuropathic rats: contributions of spinal and peripheral CB(2) receptors.
Topics: Action Potentials; Animals; Camphanes; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Ganglia, Spinal; Male; Neurons; Peripheral Nervous System Diseases; Physical Stimulation; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB2; Rimonabant; Spinal Cord; Thiazoles | 2009 |
Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain.
Topics: Analysis of Variance; Animals; Anxiety; Behavior, Animal; Biogenic Amines; Brain Chemistry; Disease Models, Animal; Dose-Response Relationship, Drug; Exploratory Behavior; Locomotion; Male; Maze Learning; Mice; Mice, Knockout; Piperidines; Prosencephalon; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Statistics as Topic | 2009 |
Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice.
Topics: Adiponectin; Animals; Anti-Obesity Agents; Dietary Fats; Disease Models, Animal; Eating; Glucose; Glucose Tolerance Test; Hyperinsulinism; Insulin; Insulin Resistance; Intra-Abdominal Fat; Lipids; Liver; Male; Mice; Mice, Knockout; Obesity; Piperidines; Pyrazoles; Rimonabant; Subcutaneous Fat; Weight Loss | 2009 |
Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model.
Topics: Animals; Animals, Newborn; Anticonvulsants; Craniocerebral Trauma; Disease Models, Animal; Electroencephalography; Epilepsy, Post-Traumatic; Pentobarbital; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Hypokinesia; Levodopa; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptor, Cannabinoid, CB1; Rimonabant | 2009 |
Effects of chronic treatment with the CB1 antagonist, rimonabant on the blood pressure, and vascular reactivity of obese Zucker rats.
Topics: Acetylcholine; Animals; Aorta; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Heart Rate; Indomethacin; Mesenteric Arteries; NG-Nitroarginine Methyl Ester; Obesity; Phenylephrine; Piperidines; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Vasoconstriction; Vasodilation | 2009 |
The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse.
Topics: Animals; Behavior, Addictive; Cocaine; Cocaine-Related Disorders; Conditioning, Operant; Corn Oil; Cues; Dietary Sucrose; Disease Models, Animal; Extinction, Psychological; Food, Formulated; Male; Mice; Mice, Inbred C57BL; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Recurrence; Reinforcement Schedule; Rimonabant; Self Administration; Water | 2009 |
Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?
Topics: Amides; Animals; Atherosclerosis; Cannabinoid Receptor Modulators; Disease Models, Animal; Endocannabinoids; Humans; Macrophages; Mice; Piperidines; Pyrazoles; Pyridines; Reactive Oxygen Species; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Signal Transduction | 2009 |
Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.
Topics: Amides; Analysis of Variance; Animals; Autoradiography; Benzoxazines; Body Weight; Brain; Cyclohexanols; Diet Fads; Disease Models, Animal; Eating; Female; Guanosine 5'-O-(3-Thiotriphosphate); International Cooperation; Morpholines; Naphthalenes; Obesity; Piperidines; Protein Binding; Pyrazoles; Pyridines; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Sulfur Isotopes; Time Factors; Tomography Scanners, X-Ray Computed; Tritium; Whole Body Imaging | 2010 |
WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction.
Topics: Acetylcholine; Animals; Benzoxazines; Cannabinoid Receptor Agonists; Cholinergic Antagonists; Disease Models, Animal; Dizocilpine Maleate; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Learning Disabilities; Male; Maze Learning; Memory; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Rats; Rimonabant; Scopolamine; Spatial Behavior | 2010 |
Δ⁹-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats.
Topics: Animals; Cerebral Cortex; Competitive Bidding; Disease Models, Animal; Dronabinol; Drug Interactions; Epilepsy; Evoked Potentials; Female; Guanosine 5'-O-(3-Thiotriphosphate); In Vitro Techniques; Male; Pentylenetetrazole; Phosphorus Isotopes; Piperidines; Pyrazoles; Rats; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
The combination of selective inhibition of the cannabinoid CB1 receptor and activation of the cannabinoid CB2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of spinal cord injury.
Topics: Animals; Autonomic Nervous System; Disease Models, Animal; Drug Therapy, Combination; Female; Mice; Mice, Inbred C57BL; Motor Activity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Spinal Cord Injuries; Urinary Bladder | 2009 |
Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice.
Topics: Analgesics; Animals; Arachidonic Acids; Benzoxazines; Cannabinoid Receptor Modulators; Cell Membrane; Constriction; Disease Models, Animal; Endocannabinoids; Glycerides; Guanosine 5'-O-(3-Thiotriphosphate); Male; Mice; Mice, Inbred Strains; Models, Neurological; Morpholines; Naphthalenes; Pain; Piperidines; Polyunsaturated Alkamides; Prefrontal Cortex; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sulfur Radioisotopes; Tritium | 2010 |
Depression-like phenotype following chronic CB1 receptor antagonism.
Topics: Analysis of Variance; Animals; Brain-Derived Neurotrophic Factor; Cell Proliferation; Cell Survival; Cytokines; Disease Models, Animal; Flow Cytometry; Food Preferences; Frontal Lobe; Immobility Response, Tonic; Male; Microdialysis; Phenotype; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Stress, Psychological; Sucrose; Sweetening Agents; Swimming | 2010 |
Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; Glucose Tolerance Test; Immunohistochemistry; Inflammation; Male; Neurons; Peripheral Nerves; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Skin; Streptozocin; Time Factors; Tumor Necrosis Factor-alpha | 2010 |
Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome.
Topics: Animals; Biomarkers; Blood Vessels; Body Weight; Cannabinoid Receptor Antagonists; Disease Models, Animal; Eating; Inflammation; Insulin Resistance; Intestinal Mucosa; Kidney Diseases; Kidney Glomerulus; Lipid Metabolism; Male; Metabolic Syndrome; Myocardial Ischemia; Piperidines; Prediabetic State; Pyrazoles; Rats; Rats, Mutant Strains; Renal Circulation; Rimonabant; Sclerosis; Thrombosis | 2010 |
CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model.
Topics: Animals; Arachidonic Acids; Cell Death; Cisplatin; Disease Models, Animal; Endocannabinoids; Glycerides; Inflammation; Kidney; Male; Mice; Mice, Knockout; Morpholines; Nephritis; Oxidative Stress; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction | 2010 |
The effect of the cannabinoid-receptor antagonist, SR141716, on the early stage of kainate-induced epileptogenesis in the adult rat.
Topics: Age Factors; Animals; Brain; Cannabinoid Receptor Antagonists; Convulsants; Disease Models, Animal; Electroencephalography; Epilepsy; Kainic Acid; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Recurrence; Rimonabant; Status Epilepticus | 2010 |
The endocannabinoid system links gut microbiota to adipogenesis.
Topics: Adipogenesis; Adipose Tissue; Animals; Arachidonic Acids; Bacterial Translocation; Caco-2 Cells; Cannabinoid Receptor Modulators; Disease Models, Animal; Dronabinol; Endocannabinoids; Glycerides; Humans; Intestinal Mucosa; Intestines; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Myeloid Differentiation Factor 88; Obesity; Permeability; Piperidines; Polyunsaturated Alkamides; Prebiotics; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger | 2010 |
Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Carrageenan; Chromatography, Liquid; Disease Models, Animal; Drug Administration Routes; Drug Administration Schedule; Endocannabinoids; Enzyme Inhibitors; Escape Reaction; Ethylene Glycols; Feeding Behavior; Formaldehyde; Gene Expression Regulation; Hyperalgesia; Indoles; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mice, Knockout; Monoacylglycerol Lipases; Motor Activity; Oncogene Proteins v-fos; Pain; Pain Measurement; Pain Threshold; Peripheral Nervous System Diseases; Piperidines; Polyunsaturated Alkamides; PPAR alpha; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant; Sciatica; Spinal Cord; Statistics, Nonparametric; Time Factors; Tissue Distribution; Tritium | 2010 |
Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
Topics: Adipose Tissue; Animals; Anti-Obesity Agents; Chemokine CCL2; Diet; Dietary Fats; Disease Models, Animal; Energy Intake; Inflammation; Liver; Mice; Mice, Inbred C57BL; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Weight Gain; Weight Loss | 2011 |
The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dronabinol; Dyskinesia, Drug-Induced; Levodopa; Male; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant | 2010 |
Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice.
Topics: Analysis of Variance; Animals; Body Weight; Diet; Disease Models, Animal; Gene Expression Regulation; Hypothalamus; Leptin; Mice; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Signal Transduction | 2011 |
Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.
Topics: Amidohydrolases; Animals; Anti-Anxiety Agents; Anxiety Disorders; Benzodioxoles; Cannabinoid Receptor Modulators; Diazepam; Disease Models, Animal; Dronabinol; Endocannabinoids; Enzyme Inhibitors; Male; Mice; Mice, Inbred C57BL; Monoacylglycerol Lipases; Obsessive-Compulsive Disorder; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2011 |
Innate difference in the endocannabinoid signaling and its modulation by alcohol consumption in alcohol-preferring sP rats.
Topics: Alcohol Drinking; Analysis of Variance; Animals; Arachidonic Acids; Blotting, Western; Brain; Cannabinoid Receptor Modulators; Central Nervous System Depressants; Disease Models, Animal; Endocannabinoids; Ethanol; Male; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Inbred Strains; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction | 2012 |
CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Female; Histamine H1 Antagonists; Hypersensitivity; Injections, Intraperitoneal; Injections, Intraventricular; Injections, Spinal; Injections, Subcutaneous; Loratadine; Male; Mast Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Pain; Piperidines; Pruritus; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2011 |
Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morphine; Pain; Pain Measurement; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2011 |
Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice.
Topics: Adipose Tissue; Animals; Diet, High-Fat; Disease Models, Animal; Fatty Liver; Glucose Intolerance; Glucose Tolerance Test; Inflammation; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Obesity, Morbid; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2011 |
Endocannabinoid system protects against cryptogenic seizures.
Topics: Administration, Oral; Animals; Brain; Cannabinoid Receptor Modulators; Disease Models, Animal; Drug Administration Schedule; Electroencephalography; Endocannabinoids; Female; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Seizures; Time Factors | 2011 |
The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors.
Topics: Analysis of Variance; Animals; Arachidonic Acids; Body Temperature Regulation; Brain; Camphanes; Capsaicin; Disease Models, Animal; Diterpenes; Endocannabinoids; Female; Hypothermia; Injections, Intraperitoneal; Injections, Intravenous; Injections, Intraventricular; Lipopolysaccharides; Male; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Long-Evans; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Signal Transduction; Sulfonamides; Time Factors; TRPV Cation Channels | 2011 |
Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation.
Topics: Animals; Arachidonic Acids; Benzodioxoles; Colitis; Disease Models, Animal; Endocannabinoids; Endotoxemia; Enzyme Inhibitors; Glycerides; Humans; Indoles; Inflammation; Inflammation Mediators; Inflammatory Bowel Diseases; Male; Mice; Mice, Inbred C57BL; Monoacylglycerol Lipases; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Trinitrobenzenesulfonic Acid | 2011 |
Pro-epileptic effects of the cannabinoid receptor antagonist SR141716 in a model of audiogenic epilepsy.
Topics: Acoustic Stimulation; Acute Disease; Animals; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Epilepsy, Reflex; Kindling, Neurologic; Limbic System; Male; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Seizures | 2011 |
Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist.
Topics: Analysis of Variance; Animals; Cells, Cultured; Cytokines; Disease Models, Animal; Embryo, Mammalian; Encephalomyelitis, Autoimmune, Experimental; Enzyme-Linked Immunosorbent Assay; Female; Glycoproteins; Hippocampus; Mice; Mice, Inbred C57BL; Myelin-Oligodendrocyte Glycoprotein; Neuroglia; Neurons; Peptide Fragments; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; RNA, Messenger; Spinal Cord; Spleen | 2012 |
Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Carbohydrate Metabolism; Cholesterol; Disease Models, Animal; Dyslipidemias; Fatty Liver; Gene Expression Regulation; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; Oxygen Consumption; Piperidines; Protein Kinases; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Tissue Culture Techniques | 2012 |
Rimonabant reduces the essential value of food in the genetically obese Zucker rat: an exponential demand analysis.
Topics: Analysis of Variance; Animals; Cannabinoids; Conditioning, Operant; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Eating; Feeding Behavior; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Reinforcement Schedule; Rimonabant | 2012 |
Cannabinoid CB₁ receptor restrains accentuated activity of hypothalamic corticotropin-releasing factor and brainstem tyrosine hydroxylase neurons in endotoxemia-induced hypophagia in rats.
Topics: Animals; Anorexia Nervosa; Body Weight; Brain Stem; Cell Count; Corticosterone; Corticotropin-Releasing Hormone; Disease Models, Animal; Eating; Endotoxemia; Gene Expression Regulation; Hypothalamus; Lipopolysaccharides; Male; Melanocyte-Stimulating Hormones; Microdialysis; Neurons; Oncogene Proteins v-fos; Piperidines; Pyrazoles; Radioimmunoassay; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Time Factors; Tyrosine 3-Monooxygenase | 2012 |
Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis.
Topics: Animals; Carbon Tetrachloride; Disease Models, Animal; Drug Evaluation, Preclinical; Extracellular Matrix; Hepatic Stellate Cells; Liver Cirrhosis, Experimental; Male; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Remission Induction; Rimonabant | 2012 |
CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.
Topics: Abdominal Fat; Adiponectin; Animals; Blood Glucose; Body Composition; Cannabinoid Receptor Antagonists; Dietary Fats; Disease Models, Animal; Dogs; Energy Intake; Fatty Acids, Nonesterified; Glucose Clamp Technique; Insulin; Insulin Resistance; Liver; Male; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2012 |
Changes in cannabinoid receptor subtype 1 activity and interaction with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-rostral ventromedial medulla pathway in a rodent neuropathic pain model.
Topics: Analgesics; Animals; Benzoxazines; Disease Models, Animal; Drug Interactions; Excitatory Amino Acid Antagonists; Male; Medulla Oblongata; Morpholines; Naphthalenes; Neuralgia; Periaqueductal Gray; Piperidines; Pyrazoles; Pyridines; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rimonabant | 2012 |
Cannabinoid receptors mediate methamphetamine induction of high frequency gamma oscillations in the nucleus accumbens.
Topics: Animals; Brain Waves; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Central Nervous System Stimulants; Disease Models, Animal; Dose-Response Relationship, Drug; Interneurons; Male; Methamphetamine; Nerve Tissue Proteins; Neurotoxicity Syndromes; Nucleus Accumbens; Piperidines; Psychomotor Performance; Psychotic Disorders; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptors, Cannabinoid; Rimonabant | 2012 |
Antidepressant-like effects of Δ⁹-tetrahydrocannabinol and rimonabant in the olfactory bulbectomised rat model of depression.
Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Cannabinoid Receptor Antagonists; Depression; Disease Models, Animal; Dronabinol; Frontal Lobe; Hippocampus; Male; MAP Kinase Signaling System; Olfactory Bulb; Piperidines; Pyrazoles; Rats; Rimonabant | 2012 |
Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.
Topics: Animals; Cannabidiol; Cannabinoid Receptor Antagonists; Disease Models, Animal; Emotions; Male; Piperidines; Pyrazoles; Rats, Wistar; Rimonabant; Schizophrenia; Schizophrenic Psychology | 2012 |
Inhibition of fatty acid amide hydrolase by URB597 attenuates the anxiolytic-like effect of acetaminophen in the mouse elevated plus-maze test.
Topics: Acetaminophen; Amidohydrolases; Animals; Anti-Anxiety Agents; Anxiety; Arachidonic Acids; Benzamides; Carbamates; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intraperitoneal; Male; Maze Learning; Mice; Mice, Inbred BALB C; Motor Activity; Piperidines; Pyrazoles; Rimonabant | 2012 |
NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
Topics: Analysis of Variance; Animals; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Body Weight; Brain-Derived Neurotrophic Factor; Cannabinoid Receptor Antagonists; Cholesterol; Dietary Fats; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypothalamus; Indazoles; Intra-Abdominal Fat; Liver; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factor; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Serotonin Plasma Membrane Transport Proteins; Thiophenes; Transaminases; Triglycerides | 2012 |
Interactions of CB1 and mGlu5 receptor antagonists in food intake, anxiety and memory models in rats.
Topics: Animals; Anxiety; Disease Models, Animal; Fear; Feeding Behavior; Male; Memory; Piperidines; Pyrazoles; Pyridines; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Rimonabant; Thiazoles | 2012 |
Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behaviour in female rats.
Topics: Animals; Behavior, Animal; Binge-Eating Disorder; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug Inverse Agonism; Drug Tolerance; Endocannabinoids; Energy Intake; Feeding Behavior; Female; Margarine; Piperidines; Pyrazoles; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Weight Loss | 2013 |
Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability.
Topics: Animals; Anxiety; Behavior, Animal; Cannabidiol; Cannabinoid Receptor Antagonists; Cannabinoids; Disease Models, Animal; Dronabinol; Drug Administration Schedule; Drug Inverse Agonism; Male; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant; Saccharin; Taste; Taste Perception | 2013 |
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system.
Topics: Animals; Anti-Anxiety Agents; Bromodeoxyuridine; Camphanes; Cannabidiol; Cannabinoid Receptor Antagonists; Cell Cycle; Cell Line, Transformed; Cell Proliferation; Disease Models, Animal; Feeding Behavior; Glial Fibrillary Acidic Protein; Hippocampus; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurogenesis; Piperidines; Pyrazoles; Rimonabant; Stress, Psychological; Thymidine Kinase | 2013 |
Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia.
Topics: Animals; Benzoxazines; Cannabidiol; Cannabinoid Receptor Modulators; Cannabinoids; Chorea; Cricetinae; Disease Models, Animal; Dystonia; Female; Male; Mesocricetus; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2002 |
Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea.
Topics: Animals; Antiemetics; Avoidance Learning; Behavior, Animal; Cannabinoids; Conditioning, Psychological; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Lithium; Male; Nausea; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant | 2003 |
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids, Neutral; Animals; Arachidonic Acids; Basal Ganglia; Cannabinoid Receptor Modulators; Capsaicin; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Dopamine; Endocannabinoids; gamma-Aminobutyric Acid; Huntington Disease; Hyperkinesis; Male; Motor Activity; Nitro Compounds; Palmitates; Piperidines; Propionates; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2003 |
A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation.
Topics: Analgesics; Animals; Behavior, Animal; Benzoxazines; Camphanes; Cannabinoids; Carrageenan; Disease Models, Animal; Drug Administration Routes; Drug Interactions; Edema; Functional Laterality; Gene Expression Regulation; Immunohistochemistry; Inflammation; Male; Mechanoreceptors; Morpholines; Naphthalenes; Pain; Pain Measurement; Physical Stimulation; Piperidines; Proto-Oncogene Proteins c-fos; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant; Spinal Cord; Time Factors | 2003 |
The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.
Topics: 3T3 Cells; Adipocytes; Adiponectin; Adipose Tissue; Animals; Body Weight; Cannabinoids; Cells, Cultured; Disease Models, Animal; Gene Expression; Hyperinsulinism; Intercellular Signaling Peptides and Proteins; Male; Mice; Obesity; Piperidines; Protein Biosynthesis; Proteins; Pyrazoles; Rats; Rats, Zucker; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; RNA, Messenger | 2003 |
The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression.
Topics: Animals; Atropine Derivatives; Benzoxazines; Bradycardia; Cannabinoids; Cardiovascular System; Cyclohexanols; Disease Models, Animal; Dose-Response Relationship, Drug; Hypotension; Male; Medulla Oblongata; Microinjections; Morpholines; Naphthalenes; Norepinephrine; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Sympathetic Fibers, Postganglionic; Sympathetic Nervous System | 2003 |
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.
Topics: Animals; Benzoxazines; Calcium Channel Blockers; Camphanes; Cannabinoids; Carrageenan; Catalepsy; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Fibrosarcoma; Haloperidol; Hand Strength; Humerus; Hyperalgesia; Male; Mice; Mice, Inbred C3H; Morpholines; Myositis; Naphthalenes; Neoplasm Transplantation; Neoplasms; Pain; Piperidines; Psychomotor Performance; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2003 |
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation.
Topics: Analgesics; Animals; Camphanes; Cannabinoids; Carrageenan; Disease Models, Animal; Drug Interactions; Hyperalgesia; Inflammation; Male; Nociceptors; Pain; Pain Threshold; Piperidines; Posterior Horn Cells; Proto-Oncogene Proteins c-fos; Pyrazoles; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2003 |
Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia.
Topics: Animals; Animals, Newborn; Asphyxia Neonatorum; Benzoxazines; Body Weight; Brain; Cannabinoids; Disease Models, Animal; Female; Humans; Hypoxia-Ischemia, Brain; Infant, Newborn; Male; Morpholines; Naphthalenes; Nerve Degeneration; Neurons; Neuroprotective Agents; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2003 |
Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.
Topics: Animals; Cannabinoid Receptor Modulators; Cannabinoids; Corpus Striatum; Disease Models, Animal; Dronabinol; Electron Transport Complex II; Enzyme Inhibitors; Huntington Disease; Male; Malonates; Multienzyme Complexes; Oxidoreductases; Piperidines; Psychotropic Drugs; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Succinate Dehydrogenase | 2003 |
Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Benzazepines; Benzoxazines; Brain Chemistry; Cannabinoid Receptor Modulators; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Dyskinesias; Endocannabinoids; Gas Chromatography-Mass Spectrometry; Levodopa; Male; Morpholines; Mouth; Naphthalenes; Oxidopamine; Parkinson Disease; Piperidines; Pyrazoles; Raclopride; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Substantia Nigra; Time Factors | 2003 |
Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?
Topics: Acute Disease; Animals; Arachidonic Acids; Brain Ischemia; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dizocilpine Maleate; Endocannabinoids; Ethanolamines; Excitatory Amino Acid Antagonists; Extracellular Fluid; Male; Microdialysis; Phospholipids; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, N-Methyl-D-Aspartate; Rimonabant; Signal Transduction; Stroke | 2004 |
Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats.
Topics: Animals; Autonomic Fibers, Postganglionic; Autonomic Fibers, Preganglionic; Blood Pressure; Camphanes; Capsaicin; Decerebrate State; Disease Models, Animal; Electric Stimulation; Germany; Imidazoles; Infusions, Intravenous; Lipopolysaccharides; Male; Norepinephrine; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, Presynaptic; Rimonabant; Shock, Septic; Solvents; Thiourea; Vagotomy; Vasomotor System; Vasopressins | 2004 |
Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model.
Topics: Animals; Disease Models, Animal; Globus Pallidus; Male; Microinjections; Motor Activity; Neostriatum; Parkinsonian Disorders; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptors, Dopamine D1; Receptors, Dopamine D2; Rimonabant; Subthalamic Nucleus | 2004 |
Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid.
Topics: Age Factors; Amyotrophic Lateral Sclerosis; Animals; Cannabinoids; Cell Count; Cell Death; Cell Survival; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Embryo, Mammalian; Humans; L-Lactate Dehydrogenase; Mice; Mice, Transgenic; Motor Neurons; Piperidines; Psychomotor Performance; Pyrazoles; Rimonabant; Spinal Cord; Superoxide Dismutase; tert-Butylhydroperoxide; Time Factors | 2004 |
Cannabinoid receptor agonists inhibit sensory nerve activation in guinea pig airways.
Topics: Analysis of Variance; Animals; Benzoxazines; Camphanes; Cannabinoid Receptor Antagonists; Disease Models, Animal; Electric Stimulation; Guinea Pigs; Male; Morpholines; Muscle Contraction; Muscle Relaxation; Muscle, Smooth; Naphthalenes; Neurokinin A; Piperidines; Probability; Pyrazoles; Respiratory Muscles; Rimonabant; Sensitivity and Specificity; Sensory Receptor Cells | 2004 |
Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.
Topics: Administration, Oral; Animals; Camphanes; Cannabidiol; Capsaicin; Carrageenan; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hyperalgesia; Inflammation; Italy; Male; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Receptors, Drug; Rimonabant; Time Factors | 2004 |
Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine.
Topics: Animals; Behavior, Animal; Cannabinoid Receptor Antagonists; Cannabinoid Receptor Modulators; Disease Models, Animal; Endocannabinoids; Morphine; Piperidines; Pyrazoles; Rats; Receptors, Cannabinoid; Rimonabant | 2004 |
Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain.
Topics: Action Potentials; Animals; Camphanes; Cannabinoids; Carrageenan; Disease Models, Animal; Inflammation; Ligation; Male; Neural Inhibition; Neuralgia; Nociceptors; Peripheral Nervous System Diseases; Physical Stimulation; Piperidines; Posterior Horn Cells; Pyrazoles; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Sensory Receptor Cells; Spinal Nerves | 2004 |
Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia.
Topics: Animals; Arachidonic Acids; Benzofurans; Benzoxazines; Blood Pressure; Brain Chemistry; Brain Infarction; Chromatography, Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Endocannabinoids; Hemodynamics; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Male; Mass Spectrometry; Morpholines; Naphthalenes; Neurologic Examination; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Reperfusion Injury; Rimonabant; Tetrazolium Salts; Time Factors | 2004 |
Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism.
Topics: Analysis of Variance; Animals; Body Temperature; Brain Infarction; Cannabidiol; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Fever; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Tetrazolium Salts; Time Factors | 2004 |
A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena.
Topics: Animals; Anticonvulsants; Arachidonic Acids; Basal Ganglia; Borna Disease; Cannabinoid Receptor Modulators; Convulsants; Disease Models, Animal; Endocannabinoids; Limbic System; Male; Movement Disorders; Naloxone; Narcotic Antagonists; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Inbred Lew; Receptor, Cannabinoid, CB1; Rimonabant; Seizures | 2005 |
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Autoradiography; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electrochemistry; gamma-Aminobutyric Acid; Gene Expression; Glutamic Acid; In Situ Hybridization; Injections, Intraventricular; Male; Motor Activity; Oxidopamine; Parkinson Disease; Piperidines; Protein Binding; Pyrazoles; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Cannabinoid, CB1; Rimonabant; RNA, Messenger; Rotarod Performance Test; Superoxide Dismutase; Superoxide Dismutase-1; Tyrosine 3-Monooxygenase | 2006 |
Anxiolytic-like properties of the anandamide transport inhibitor AM404.
Topics: Animals; Animals, Newborn; Anti-Anxiety Agents; Anxiety Disorders; Anxiety, Separation; Arachidonic Acids; Behavior, Animal; Brain; Cannabinoid Receptor Modulators; Carrier Proteins; Disease Models, Animal; Endocannabinoids; Male; Maze Learning; Neural Inhibition; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Cannabinoid, CB1; Reflex, Startle; Rimonabant | 2006 |
Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats.
Topics: Anaerobiosis; Animals; Animals, Newborn; Arachidonic Acids; Benzoxazines; Brain; Brain Chemistry; Brain Ischemia; Cannabinoid Receptor Agonists; Cannabinoids; Disease Models, Animal; Hypoxia, Brain; L-Lactate Dehydrogenase; Morpholines; Naphthalenes; Neuroprotective Agents; Nitric Oxide Synthase Type II; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Tumor Necrosis Factor-alpha | 2006 |
Obesity drug development - CBI's 2nd Annual Summit.
Topics: Adipocytes; Animals; Anti-Obesity Agents; Cannabinoid Receptor Modulators; Disease Models, Animal; Drug Design; Estrone; Fatty Acids; Humans; Obesity; Oleic Acids; Oxidation-Reduction; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2006 |
Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system.
Topics: Action Potentials; Analysis of Variance; Animals; Arachidonic Acids; Behavior, Animal; Benzoxazines; Cannabinoid Receptor Modulators; Disease Models, Animal; Drug Interactions; Endocannabinoids; Hot Temperature; Hyperalgesia; Male; Microdialysis; Morpholines; Naphthalenes; Neurons; Pain Measurement; Piperidines; Pyrazoles; Raphe Nuclei; Rats; Rats, Wistar; Reaction Time; Rimonabant; Sciatic Neuropathy; Serotonin; Touch | 2006 |
Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy.
Topics: Action Potentials; Animals; Animals, Newborn; Benzoxazines; Cells, Cultured; Disease Models, Animal; Drug Interactions; Epilepsy; Hippocampus; Morpholines; Naphthalenes; Neurons; Patch-Clamp Techniques; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Synaptic Transmission | 2007 |
SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats.
Topics: Alcoholism; Animals; Disease Models, Animal; Food Preferences; Male; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Rimonabant; Sucrose | 2006 |
A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide.
Topics: Animals; Benzoxazines; Binding, Competitive; Body Temperature; Camphanes; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dronabinol; Fever; Interleukin-6; Lipopolysaccharides; Male; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant | 2007 |
Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.
Topics: Animals; Brain; Cannabinoid Receptor Antagonists; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Phencyclidine; Piperidines; Psychoses, Substance-Induced; Pyrazoles; Rats; Receptors, Cannabinoid; Reflex, Startle; Rimonabant; Schizophrenia; Sensation Disorders; Synaptic Transmission | 2007 |
[Endocannabinoids: therapeutic perspectives in chronic liver diseases].
Topics: Animals; Appetite Depressants; Cannabinoid Receptor Modulators; Cannabinoids; Chronic Disease; Disease Models, Animal; Disease Progression; Endocannabinoids; Fatty Liver; Glycolysis; Hepatitis C, Chronic; Hepatocytes; Humans; Hypertension, Portal; Lipogenesis; Liver; Liver Cirrhosis; Liver Diseases; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2007 |
Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism.
Topics: Animals; Behavior, Animal; Cannabidiol; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Functional Laterality; Glutamic Acid; Infarction, Middle Cerebral Artery; Male; Mice; Motor Activity; Neuroprotective Agents; Perfusion; Peroxidase; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Tetrazolium Salts; Time Factors | 2007 |
The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
Topics: Analysis of Variance; Animals; Behavior, Animal; Body Water; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Eating; Endocannabinoids; Gene Expression Regulation, Enzymologic; Lipid Metabolism; Male; Metabolism; Obesity; Oleic Acids; Piperidines; Pyrazoles; Rats; Rats, Wistar; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Stearoyl-CoA Desaturase; Time Factors | 2008 |
Attenuation of allergic contact dermatitis through the endocannabinoid system.
Topics: Animals; Arachidonic Acids; Camphanes; Cannabinoid Receptor Modulators; Cannabinoids; Chemokines; Dermatitis, Allergic Contact; Dinitrofluorobenzene; Disease Models, Animal; Down-Regulation; Dronabinol; Endocannabinoids; Female; Glycerides; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant; Skin; Up-Regulation | 2007 |
Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux.
Topics: Airway Obstruction; Animals; Benzoxazines; Bronchi; Bronchoconstriction; Camphanes; Cannabinoids; Capillary Permeability; Disease Models, Animal; Dose-Response Relationship, Drug; Esophagus; Extravasation of Diagnostic and Therapeutic Materials; Gastroesophageal Reflux; Guinea Pigs; Hydrochloric Acid; Male; Morpholines; Naphthalenes; Piperidines; Pulmonary Edema; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Respiratory Function Tests; Rimonabant; Trachea | 2007 |
Significance of cannabinoid CB1 receptors in improgan antinociception.
Topics: Analgesics; Analysis of Variance; Animals; Cimetidine; Disease Models, Animal; Dose-Response Relationship, Drug; Guanosine 5'-O-(3-Thiotriphosphate); Injections, Intraventricular; Male; Pain; Pain Measurement; Pain Threshold; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors | 2007 |
The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation.
Topics: Acute Disease; Animals; Biphenyl Compounds; Body Temperature; Camphanes; Carrageenan; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Hindlimb; Hyperalgesia; Inflammation; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Monoacylglycerol Lipases; Pain; Pain Measurement; Pain Threshold; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Rimonabant | 2007 |
Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Topics: Amidohydrolases; Analysis of Variance; Animals; Anxiety; Arachidonic Acids; Behavior, Animal; Benzamides; Carbamates; Disease Models, Animal; Endocannabinoids; Glycerides; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |
Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
Topics: Adiponectin; Animals; Body Weight; Disease Models, Animal; Eating; Kidney; Kidney Failure, Chronic; Lipids; Male; Obesity; Piperidines; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Survival Analysis | 2007 |
Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice.
Topics: Adaptation, Psychological; Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Corticosterone; Depression; Desipramine; Disease Models, Animal; Female; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Signal Transduction; Statistics, Nonparametric; Stress, Psychological; Swimming; Time Factors | 2008 |
Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala.
Topics: Amygdala; Animals; Conditioning, Operant; Cues; Disease Models, Animal; Dose-Response Relationship, Drug; Extinction, Psychological; Heroin; Heroin Dependence; Male; Motivation; Narcotics; Nucleus Accumbens; Piperidines; Prefrontal Cortex; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Reinforcement, Psychology; Reward; Rimonabant | 2008 |
Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant.
Topics: Analgesics, Opioid; Animals; Brain; Brain Chemistry; Cannabinoid Receptor Modulators; Cues; Disease Models, Animal; Dronabinol; Drug Administration Schedule; Male; Marijuana Abuse; Morphine; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Reinforcement, Psychology; Rimonabant; Saimiri; Secondary Prevention; Self Administration | 2008 |
Cannabinoids provoke alcoholic steatosis through a conspiracy of neighbors.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Carnitine O-Palmitoyltransferase; Cells, Cultured; Diet, Fat-Restricted; Disease Models, Animal; Endocannabinoids; Ethanol; Fatty Acid Synthases; Fatty Acids; Fatty Liver, Alcoholic; Glycerides; Hepatocytes; Humans; Lipogenesis; Lipoprotein Lipase; Liver; Mice; Oxidation-Reduction; Paracrine Communication; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sterol Regulatory Element Binding Protein 1; Up-Regulation | 2008 |
Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver.
Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Carnitine O-Palmitoyltransferase; Cells, Cultured; Coculture Techniques; Diet, Fat-Restricted; Disease Models, Animal; Endocannabinoids; Ethanol; Fatty Acid Synthases; Fatty Acids; Fatty Liver, Alcoholic; Glycerides; Hepatocytes; Lipogenesis; Lipoprotein Lipase; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidation-Reduction; Paracrine Communication; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sterol Regulatory Element Binding Protein 1; Up-Regulation | 2008 |
Rimonabant in rats with a metabolic syndrome: good news after the depression.
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Depression; Disease Models, Animal; Inflammation Mediators; Leukocytes; Metabolic Syndrome; Piperidines; Platelet Activation; Platelet Aggregation Inhibitors; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |
Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.
Topics: Acetylcholine; Amidohydrolases; Animals; Cannabidiol; Cannabis; Cholinergic Agents; Croton Oil; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gastrointestinal Agents; Gastrointestinal Motility; Gastrointestinal Transit; Ileitis; Ileum; Loperamide; Male; Mice; Mice, Inbred ICR; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant | 2008 |
The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats.
Topics: Animals; Anti-Inflammatory Agents; Chemokine CCL2; Chemokine CCL5; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Glucose Intolerance; Inflammation Mediators; Leukocyte Count; Leukocytes; Lipids; Male; Metabolic Syndrome; Piperidines; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrazoles; Rats; Rats, Zucker; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors; Weight Gain | 2008 |
Cannabinoids control spasticity and tremor in a multiple sclerosis model.
Topics: Animals; Camphanes; Cannabinoids; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Mice; Multiple Sclerosis; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Spasm; Tremor | 2000 |
Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940.
Topics: Animals; Behavior, Animal; Brain; Cannabinoids; Cerebellum; Cerebral Cortex; Corpus Striatum; Cyclic AMP; Cyclohexanols; Disease Models, Animal; Down-Regulation; Drug Administration Schedule; Drug Tolerance; GTP-Binding Proteins; Hippocampus; Injections, Intraperitoneal; Male; Marijuana Abuse; Piperidines; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Signal Transduction | 2000 |
CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats.
Topics: Animals; Benzoxazines; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Antagonism; Injections, Intravenous; Male; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Self Administration | 1999 |
Endocannabinoids control spasticity in a multiple sclerosis model.
Topics: Amides; Animals; Arachidonic Acids; Brain; Cannabinoid Receptor Modulators; Cannabinoids; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Endocannabinoids; Ethanolamines; Glycerides; Humans; Mice; Mice, Inbred Strains; Multiple Sclerosis; Palmitic Acids; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Spasm; Spinal Cord | 2001 |
Involvement of central and peripheral cannabinoid receptors in the regulation of heart resistance to arrhythmogenic effects of epinephrine.
Topics: Animals; Arrhythmias, Cardiac; Cannabinoids; Disease Models, Animal; Dronabinol; Epinephrine; Ganglionic Blockers; Heart; Hexamethonium; Immunity, Innate; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2000 |
The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
Topics: Analgesics; Animals; Benzoxazines; Cannabinoids; Cyclohexanols; Disease Models, Animal; Dronabinol; Hyperalgesia; Morpholines; Naphthalenes; Pain Measurement; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Rimonabant; Sciatica | 2001 |
The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain.
Topics: Analgesics; Animals; Benzoxazines; Cannabinoids; Disease Models, Animal; Drug Interactions; Hyperalgesia; Male; Morpholines; Naphthalenes; Pain; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB2; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2001 |
Functional interaction between opioid and cannabinoid receptors in drug self-administration.
Topics: Animals; Avoidance Learning; Cannabinoids; Caudate Nucleus; Conditioning, Operant; Disease Models, Animal; Heroin; Heroin Dependence; Male; Mice; Morphine; Morphine Dependence; Naloxone; Narcotic Antagonists; Nucleus Accumbens; Piperidines; Putamen; Pyrazoles; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Receptors, Opioid; Rimonabant; RNA, Messenger; Self Administration; Septum of Brain | 2001 |
CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain.
Topics: Analgesia; Analgesics; Animals; Benzoxazines; Disease Models, Animal; Drug Interactions; Male; Medulla Oblongata; Morpholines; Naphthalenes; Nerve Crush; Neuralgia; Neurons; Pain Measurement; Peripheral Nervous System Diseases; Piperidines; Pyrazoles; Rats; Rats, Wistar; Reaction Time; Receptors, Cannabinoid; Receptors, Drug; Reticular Formation; Rimonabant | 2001 |
Cannabinoids inhibit nitric oxide production in bone marrow derived feline macrophages.
Topics: Animals; Bone Marrow Cells; Camphanes; Cannabinoids; Cats; Cyclohexanols; Disease Models, Animal; Feline Acquired Immunodeficiency Syndrome; Histocytochemistry; Immunosuppressive Agents; Macrophages; Nitric Oxide; Phagocytosis; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2001 |
Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation.
Topics: Analgesics; Animals; Cannabinoid Receptor Modulators; Cannabinoids; Cannabinol; Croton Oil; Cyclohexanols; Dermatologic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Gastrointestinal Motility; Inflammatory Bowel Diseases; Injections, Intraperitoneal; Injections, Intraventricular; Male; Mice; Mice, Inbred ICR; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2001 |
Cannabinoid activity curtails cocaine craving.
Topics: Animals; Cannabinoids; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dronabinol; Humans; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2001 |
A cannabinoid mechanism in relapse to cocaine seeking.
Topics: Animals; Behavior, Animal; Cannabinoid Receptor Modulators; Cannabinoids; Cocaine; Cocaine-Related Disorders; Disease Models, Animal; Dronabinol; Humans; Piperidines; Pyrazoles; Rats; Rats, Long-Evans; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Recurrence; Rimonabant | 2001 |
Exogenous anandamide protects rat brain against acute neuronal injury in vivo.
Topics: Animals; Animals, Newborn; Arachidonic Acids; Blotting, Western; Brain; Brain Edema; Brain Injuries; Cannabinoid Receptor Modulators; Cannabinoids; Disease Models, Animal; Dose-Response Relationship, Drug; Endocannabinoids; Enzyme Inhibitors; Glycerides; Longitudinal Studies; Magnetic Resonance Imaging; Microinjections; Neurons; Ouabain; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2001 |
Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors.
Topics: Animals; Arachidonic Acids; Benzoxazines; Camphanes; Cannabinoid Receptor Modulators; Capsaicin; Disease Models, Animal; Dose-Response Relationship, Drug; Genotype; Mice; Mice, Inbred Strains; Mice, Knockout; Morpholines; Multiple Sclerosis; Muscle Spasticity; Naphthalenes; Pain; Pain Measurement; Piperidines; Pyrazoles; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2002 |